PERCEPTIVE ADVISORS LLC
Q2 2021 13F-HR Holdings
Net value change ($000)
-216,830
(-2.7%)
New positions
26
Sold out positions
17
Turnover %
14.5%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2021
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| NAUT | 90,002 | NEW |
| Singular Genomics Systems, Inc. | 84,717 | NEW |
| UTHR | 81,388 | 278.0% |
| Zymergen Inc. | 65,349 | NEW |
| MDT | 55,858 | NEW |
| Cerevel Therapeutics Holdings, Inc. | 55,207 | 86.6% |
| SpringWorks Therapeutics, Inc. | 42,873 | 12.0% |
| CareMax, Inc. | 42,828 | NEW |
| APLS | 41,785 | NEW |
| Rain Oncology Inc. | 39,425 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| AVIR | -136,165 | -73.7% |
| Mirati Therapeutics, Inc. | -80,565 | -13.5% |
| Global Blood Therapeutics, Inc. | -60,712 | -29.5% |
| TVTX | -55,435 | -67.3% |
| Invitae Corp | -42,293 | -20.6% |
| ALLO | -40,376 | -100.0% |
| ARENA PHARMACEUTICALS INC | -39,900 | -100.0% |
| ACAD | -36,386 | -100.0% |
| Forma Therapeutics Holdings, Inc. | -35,025 | -100.0% |
| Inari Medical, Inc. | -31,509 | -52.1% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
16,712
(0.2% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|